Vanda Pharmaceuticals Inc. (VNDA) Shares Up 2.5%
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shot up 2.5% during mid-day trading on Thursday . The company traded as high as $11.54 and last traded at $11.44, with a volume of 216,629 shares changing hands. The stock had previously closed at $11.16.
Several research analysts recently issued reports on the company. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th. Jefferies Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Friday, June 10th. Finally, Brean Capital restated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, June 6th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Vanda Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $15.92.
The company’s market cap is $491.51 million. The stock’s 50 day moving average price is $11.13 and its 200 day moving average price is $9.19.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.07. During the same quarter in the previous year, the company earned ($0.10) EPS. The company earned $33.30 million during the quarter, compared to analysts’ expectations of $32.48 million. The firm’s quarterly revenue was up 50.0% compared to the same quarter last year. Equities research analysts forecast that Vanda Pharmaceuticals Inc. will post ($0.83) earnings per share for the current year.
A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. J. Goldman & Co LP raised its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 20.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 902,839 shares of the biopharmaceutical company’s stock after buying an additional 151,079 shares during the period. Vanda Pharmaceuticals makes up 0.9% of J. Goldman & Co LP’s investment portfolio, making the stock its 25th largest position. J. Goldman & Co LP owned 2.11% of Vanda Pharmaceuticals worth $8,405,000 as of its most recent filing with the SEC.
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.